PRINCETON, N.J., July 25 /PRNewswire-FirstCall/ -- Cytogen Corporation today announced that it will report its second-quarter 2006 financial results on Monday August 7, 2006 at approximately 4:00 p.m. EDT. The announcement will be followed by a live conference call that will begin at approximately 4:15 p.m. EDT. Michael D. Becker, president and chief executive officer will host the call and discuss the Company's financial results and business activities for the period. The conference call is expected to last one hour.
All interested parties may access the call by using the following information:
Domestic Dial-In: 800-322-5044 International Dial-In: 617-614-4927 Access Code: 11837231
A live audio of the conference call will be simultaneously broadcast over the internet and can be accessed by going to the "Investor Relations" section of the Company's website at http://www.cytogen.com.
For those unable to listen to the live audio, the event will be available for replay beginning approximately one hour after the call and continuing for seven days thereafter. The replay can be accessed using the following information:
Domestic Dial-In: 888-286-8010 International Dial-In: 617-801-6888 Access Code: 91204033 About Cytogen
Founded in 1980, Cytogen Corporation of Princeton, NJ, is a biopharmaceutical company dedicated to improving the lives of patients with cancer by acquiring, developing and commercializing innovative molecules targeting the sites and stages of cancer progression. Cytogen's marketed products include QUADRAMET(R) (samarium Sm-153 lexidronam injection), PROSTASCINT(R) (capromab pendetide) kit for the preparation of Indium In-111 capromab pendetide, and SOLTAMOX(TM) (tamoxifen citrate, oral solution 10mg/5mL) in the United States. Cytogen's development pipeline consists of CYT-500, a therapeutic radiolabeled antibody targeting prostate-specific membrane antigen (PSMA), a protein highly expressed on the surface of prostate cancer cells and the neovasculature of solid tumors. Cytogen also has exclusive United States marketing rights to COMBIDEX(R) (ferumoxtran-10) for all applications, and the exclusive right to market and sell ferumoxytol (previously Code 7228) for oncology applications in the United States. Full prescribing information for the Company's products is available at http://www.cytogen.com or by calling 800-833-3533. For more information, please visit the Company's website at http://www.cytogen.com, which is not part of this press release.
Media/Investors contact: Brian Korb The Trout Group (212) 477-9007 x23
Cytogen CorporationCONTACT: Media-Investors contact: Brian Korb for Cytogen Corporation,+1-212-477-9007 x23
Web site: http://www.cytogen.com/
